Under-the-Radar Opportunities in ETFs
Over recent years, investors have sought safety within mega-cap tech stocks while searching for alpha within disruptive technology trends like artificial intelligence. Most investors can agree the AI theme has long-term growth potential, and the current market sell-off is a short-term hiccup.
ETF Prime: Islam Shares 2025's Top Trends and ETFs
On this week's episode of ETF Prime, Roxanna Islam, CFA, CAIA, head of sector & industry research at VettaFi, joined host Nate Geraci. The two discussed top ETF performers and trends this year as well as long-established asset managers finally joining the ETF industry.
ARKG: Eyeing Favorable Macro 2025 Turns, Encouraging Momentum Trends
I maintain a buy rating on ARK Genomic Revolution ETF (ARKG) due to improving momentum, potential lower interest rates, and a favorable M&A environment in 2025. Despite a 20% decline in 2024, ARKG's technical chart shows bullish potential with key support at $21-$22 and resistance at $28. ARKG is a small, actively managed ETF focused on genomics, with high exposure to small-cap stocks and a diversified mix of value, blend, and growth.
Best-Performing ETF Areas of Last Week
Wall Street was upbeat last week with the Dow Jones and the S&P 500 hitting all-time highs last week.
Interest Rate Regimes And ARKG: Underperformance Explained
ARKG's top holdings were replaced due to poor performance, highlighting the fund's vulnerability to interest rate changes and high concentration in cash-burning companies. ARKG underperformed significantly compared to peers and the Nasdaq, especially during tighter monetary conditions, due to its concentrated portfolio and high valuation multiples. Virtus, with a more diversified and less concentrated portfolio, outperformed ARKG, suggesting that ARKG needs restructuring to better handle interest rate changes.
Almost Every Ark Fund Is Now Underperforming The Overall Market. Here's Why.
Ark Funds pull exclusively from different slivers of the technology sector that also tend to be the most volatile. Economic conditions can make a bigger performance difference over the long term than most investors might expect.
5 Technology ETFs at the Forefront of the August Rebound
Wall Street roared back after a sell-off early in the month as fears of recession eased. The technology sector, which bore the biggest brunt, rebounded strongly and once again led the market over the past week.
5 Sector ETFs That Outperformed With Double-Digit Gains in July
July witnessed the "Great Rotation" in the U.S. stock market as investors shunned the hot technology stocks in favor of smaller companies and other sectors, which are the bigger beneficiaries of the Fed rate cuts.
ARKG: A Genomics Play But Active Isn't Adding Value
Genomics is rapidly advancing, shaping our understanding of health, disease, and life itself. Consider investing in the ARK Genomic Revolution ETF for exposure to leading genomics companies. ARKG's active management may not be outperforming compared to passive genomics ETFs like PBE, with potential regulatory and concentration risks.
